MET and lung adenocarcinoma: Owing to the great importance of the FOXM1/MET/AKT axis in lung adenocarcinoma, our findings strongly indicate that targeting FOXM1 may be a promising therapeutic strategy for overcoming gefitinib resistance in lung adenocarcinoma.